Various recent technology news / studies that may be of interest.
Study examines the impact of fake online reviews on sales
New research exposes the pervasive practice of fake online product reviews
Can you really trust that online product review before you make a purchase decision? New research has found that the practice of faking online product reviews may be more pervasive than you think.
According to researchers from UCLA Anderson School of Management, andthe Marshall School of Business at the University of Southern California (USC), a wide array of product marketers actually purchases fake online reviews through an online marketplace found through social media. As a result, marketers receive many reviews and high-average ratings on e-commerce sites that include Amazon, Walmart and Wayfair, among others.
The study, published in the current issue of the INFORMS journal Marketing Science, offers:
- There’s a large online marketplace for the selling and buying of fake online reviews.
- Fake online reviews do contribute to better ratings and sales for product sellers.
- Most major brands do not engage in the practice of buying fake reviews.
- Online marketplaces work to regulate online fake reviews, but there is lag time in enforcement.
Noble Introduces Mental Health Technology To Reduce Misdiagnosed And Underserved Patients In Primary Care
Noble is an AI, and objective data-driven mental health app, announced the launch of a new offering for primary care physicians and mental health professionals that provides remotely monitored, preventative, and early intervention support for acute or chronic mental health conditions.
According to the app creators, it consists of four-part remote patient monitoring model combines innovative technology with trained mental health professionals to impact outcomes in a lasting, meaningful way:
- Assess: Subjective data gathering through client self-reporting and objective data gathering through hair cortisol concentration tests, heart rate variability (HRV), and voice as a digital biomarker.
- Support: AI-driven care provider dashboard that shares the remotely monitored objective data stream to offer remote insights and real-time alerts to the care provider and team.
- Motivate: Immediate, AI-driven treatment, protocol-driven and therapeutic interventions based on patient needs.
- Connect: Human-to-human monitoring and coaching support guided by additional understanding through voice analysis, and AI-supported technology.
Magnus Medical announced today that it received FDA 510(k) clearance for its Saint neuromodulation system.
The Saint neurostimulation platform is for the treatment of major depressive disorder (MDD). It treats adults who fail to achieve satisfactory improvement from prior antidepressant medications in the current episode.
The individualized, rapid-acting, non-invasive neurostimulation platform demonstrated the potential to be a reproducible, rapid and highly effective treatment for severe, refractory depression in a broader clinical setting. It received FDA breakthrough device designation in October 2021.
Saint combines advanced imaging technologies and personalized targeting and novel stimulation patterns. It uses structural and functional MRI to inform a proprietary algorithm. The algorithm identifies the optimal anatomic target for focused neurostimulation in people with MDD.
Results of a trial published in the American Journal of Psychiatry showed that 79% of people in the active treatment arm entered remission from their depression. That compared to 13% in the sham treatment arm. Magnus said in a news release that the new “individualized” neurostimulation provides a new option for treating depression.